{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:01:47Z","timestamp":1790262107168,"version":"4.1.0"},"reference-count":144,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS 16 R\/2018"],"award-info":[{"award-number":["DJCLS 16 R\/2018"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["European Treatment and Outcome Study of CML"],"award-info":[{"award-number":["European Treatment and Outcome Study of CML"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Myeloproliferative neoplasms (MPNs) comprise a heterogenous group of hematologic neoplasms which are divided into Philadelphia positive (Ph+), and Philadelphia negative (Ph\u2212) or classical MPNs. A variety of immunological factors including inflammatory, as well as immunomodulatory processes, closely interact with the disease phenotypes in MPNs. NK cells are important innate immune effectors and substantially contribute to tumor control. Changes to the absolute and proportionate numbers of NK cell, as well as phenotypical and functional alterations are seen in MPNs. In addition to the disease itself, a variety of therapeutic options in MPNs may modify NK cell characteristics. Reports of suppressive effects of MPN treatment strategies on NK cell activity have led to intensive investigations into the respective compounds, to elucidate the possible negative effects of MPN therapy on control of the leukemic clones. We hereby review the available literature on NK cells in Ph+ and Ph\u2212 MPNs and summarize today\u2019s knowledge on disease-related alterations in this cell compartment with particular focus on known therapy-associated changes. Furthermore, we critically evaluate conflicting data with possible implications for future projects. We also aim to highlight the relevance of full NK cell functionality for disease control in MPNs and the importance of considering specific changes related to therapy in order to avoid suppressive effects on immune surveillance.<\/jats:p>","DOI":"10.3390\/cancers13174400","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T08:42:32Z","timestamp":1630399352000},"page":"4400","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["NK Cells in Myeloproliferative Neoplasms (MPN)"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8132-5293","authenticated-orcid":false,"given":"Erin","family":"Naismith","sequence":"first","affiliation":[{"name":"Internal Medicine V, Department of Haematology and Oncology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4918-8887","authenticated-orcid":false,"given":"Janine","family":"Steichen","sequence":"additional","affiliation":[{"name":"Internal Medicine V, Department of Haematology and Oncology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2265-1974","authenticated-orcid":false,"given":"Sieghart","family":"Sopper","sequence":"additional","affiliation":[{"name":"Internal Medicine V, Department of Haematology and Oncology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria"},{"name":"Tyrolean Cancer Research Institute, Innrain 66, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[{"name":"Internal Medicine V, Department of Haematology and Oncology, Medical University Innsbruck, Anichstr. 35, 6020 Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Grabek, J., Straube, J., Bywater, M., and Lane, S.W. (2020). MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment. Cells, 9.","DOI":"10.3390\/cells9081901"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: Document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: A decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100706","DOI":"10.1016\/j.blre.2020.100706","article-title":"Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map","volume":"42","author":"Shallis","year":"2020","journal-title":"Blood Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11899-014-0228-z","article-title":"Epidemiology of MPN: What Do We Know?","volume":"9","author":"Anderson","year":"2014","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_11","first-page":"1144","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ajh.25011","article-title":"Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring","volume":"93","author":"Jabbour","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-017-0042-7","article-title":"Polycythemia vera treatment algorithm","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-018-0529-x","article-title":"Polycythemia vera","volume":"19","author":"Spivak","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMcp1816082","article-title":"Essential thrombocythemia","volume":"381","author":"Tefferi","year":"2019","journal-title":"Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-018-0142-z","article-title":"Prefibrotic myelofibrosis: Treatment algorithm","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s11899-014-0227-0","article-title":"An Immune Dysregulation in MPN","volume":"9","author":"Barosi","year":"2014","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_24","first-page":"436","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100005","DOI":"10.1016\/j.cytox.2019.100005","article-title":"Cytokines frequently implicated in myeloproliferative neoplasms","volume":"1","author":"Wang","year":"2019","journal-title":"Cytokine X"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Longhitano, L., Volti, G.L., Giallongo, C., Spampinato, M., Barbagallo, I., Di Rosa, M., Romano, A., Avola, R., Tibullo, D., and Palumbo, G.A. (2020). The Role of Inflammation and Inflammasome in Myeloproliferative Disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082334"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Braun, L.M., and Zeiser, R. (2020). Immunotherapy in Myeloproliferative Diseases. Cells, 9.","DOI":"10.3390\/cells9061559"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hasselbalch, H.C., Thomassen, M., Riley, C.H., Kj\u00e6r, L., Larsen, T.S., Jensen, M.K., Bjerrum, O.W., Kruse, T.A., and Skov, V. (2014). Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112786"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","article-title":"Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines","volume":"172","author":"Bock","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11899-019-0496-8","article-title":"Treatment-Free Remission in CML: The US Perspective","volume":"14","author":"Murthy","year":"2019","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106273","DOI":"10.1016\/j.leukres.2019.106273","article-title":"Role of cancer immunology in chronic myelogenous leukemia","volume":"88","author":"Ureshino","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood-2004-10-4035","article-title":"NK-dependent DC maturation is mediated by TNF\u03b1 and IFN\u03b3 released upon engagement of the NKp30 triggering receptor","volume":"106","author":"Vitale","year":"2005","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.3389\/fimmu.2019.01812","article-title":"On the Way to Become a Natural Killer Cell","volume":"10","author":"Mikulak","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cyto.b.21508","article-title":"Markers and function of human NK cells in normal and pathological conditions","volume":"92","author":"Marcenaro","year":"2017","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fimmu.2017.00360","article-title":"Modeling Human Natural Killer Cell Development in the Era of Innate Lymphoid Cells","volume":"8","author":"Scoville","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3389\/fimmu.2019.01569","article-title":"Bone Marrow NK Cells: Origin, Distinctive Features, and Requirements for Tissue Localization","volume":"10","author":"Bonanni","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fimmu.2017.00130","article-title":"Regulation of Murine Natural Killer Cell Development","volume":"8","author":"Goh","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"208ra145","DOI":"10.1126\/scitranslmed.3006702","article-title":"Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry","volume":"5","author":"Horowitz","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1146\/annurev.immunol.14.1.619","article-title":"Receptors for Hla Class-I Molecules in Human Natural Killer Cells","volume":"14","author":"Moretta","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: You can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.smim.2006.03.003","article-title":"Missing self recognition and self tolerance of natural killer (NK) cells","volume":"18","author":"Raulet","year":"2006","journal-title":"Semin. Immunol."},{"key":"ref_45","first-page":"1186","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nat. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.immuni.2015.04.007","article-title":"Distinct Mechanisms of Tumor Resistance to NK Killing: Of Mice and Men","volume":"42","author":"Pardoll","year":"2015","journal-title":"Immunity"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.4049\/jimmunol.176.8.5108","article-title":"BCR\/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia","volume":"176","author":"Boissel","year":"2006","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/ejh.12420","article-title":"Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-\u03b1","volume":"94","author":"Riley","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3389\/fimmu.2017.00892","article-title":"CD56 in the Immune System: More Than a Marker for Cytotoxicity?","volume":"8","author":"Capsomidis","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"34310","DOI":"10.1038\/srep34310","article-title":"CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes","volume":"6","author":"Yeap","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccell.2017.06.009","article-title":"Control of Metastasis by NK Cells","volume":"32","author":"Gonzalez","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1084\/jem.20031981","article-title":"Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and \u03b3\u03b4 T Cells","volume":"199","author":"Street","year":"2004","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3389\/fimmu.2019.02357","article-title":"Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells","volume":"10","author":"Carlsten","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11899-013-0190-1","article-title":"Immunology and Immunotherapy of Chronic Myeloid Leukemia","volume":"9","author":"Ilander","year":"2014","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1182\/blood.V92.12.4758","article-title":"Lineage involvement of stem cells bearing the philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization","volume":"92","author":"Takahashi","year":"1998","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000039748","article-title":"Detection of the BCR-ABL fusion gene in natural killer cells in patients with chronic myelogenous leukemia","volume":"104","author":"Min","year":"2000","journal-title":"Acta Haematol."},{"key":"ref_58","first-page":"216","article-title":"Ontogeny of natural killer cells and T cells by analysis of BCR\u2013ABL rearrangement from patients with chronic myelogenous leukaemia","volume":"11","author":"Cho","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4049\/jimmunol.168.2.643","article-title":"The BCR\/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients","volume":"168","author":"Nakajima","year":"2002","journal-title":"J. Immunol."},{"key":"ref_60","first-page":"165","article-title":"Lysis of fresh leukemic blasts by interferon-activated human natural killer cells","volume":"3","author":"Pattengale","year":"1983","journal-title":"Nat. Immun. Cell Growth Regul."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0145-2126(87)90158-5","article-title":"Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors","volume":"11","author":"Savary","year":"1987","journal-title":"Leuk. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1182\/blood.V87.6.2476.bloodjournal8762476","article-title":"Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture","volume":"87","author":"Cervantes","year":"1996","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4049\/jimmunol.176.2.864","article-title":"The Decreased Susceptibility of Bcr\/Abl Targets to NK Cell-Mediated Lysis in Response to Imatinib Mesylate Involves Modulation of NKG2D Ligands, GM1 Expression, and Synapse Formation","volume":"176","author":"Cebo","year":"2006","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2008-05-158253","article-title":"Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib","volume":"113","author":"Yong","year":"2009","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/leu.2017.235","article-title":"NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib","volume":"31","author":"Sopper","year":"2017","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR\u2013ABL-positive mice","volume":"26","author":"Chen","year":"2011","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-013-1483-9","article-title":"Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia","volume":"99","author":"Kumagai","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_68","first-page":"540","article-title":"Lymphocytes NK: Un r\u00f4le majeur dans le contr\u00f4le immunologique de la leuc\u00e9mie my\u00e9lo\u00efde chronique","volume":"34","author":"Toubert","year":"2018","journal-title":"J. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exphem.2013.01.008","article-title":"Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients","volume":"41","author":"Caocci","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5581\/1516-8484.20110057","article-title":"The role of natural killer cells in chronic myeloid leukemia","volume":"33","author":"Danier","year":"2011","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_71","first-page":"162","article-title":"Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors. The first molecular targeted treatment","volume":"3","author":"Bumbea","year":"2010","journal-title":"J. Med. Life"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kreutzman, A., Rohon, P., Faber, E., Indr\u00e1k, K., Juvonen, V., Kairisto, V., Voglova, J., Sinisalo, M., Flochov\u00e1, E., and Vakkila, J. (2011). Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-\u03b1 Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023022"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Ilander, M., Kreutzman, A., Rohon, P., Melo, T., Faber, E., Porkka, K., Vakkila, J., and Mustjoki, S. (2014). Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-\u03b1 Monotherapy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087794"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1080\/1042819031000110973","article-title":"Immunological effects of interferon-alpha on chronic myelogenous leukemia","volume":"44","author":"Palma","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12967-019-02194-x","article-title":"Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-\u03b1","volume":"18","author":"Alves","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","article-title":"Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets","volume":"110","author":"Rix","year":"2007","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.4049\/jimmunol.1601695","article-title":"Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages","volume":"199","author":"Bellora","year":"2017","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3109\/10428194.2011.647017","article-title":"Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib","volume":"53","author":"Hayashi","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.25233","article-title":"The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity","volume":"127","author":"Salih","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4161\/cbt.27310","article-title":"Large granular lymphocytosis during dasatinib therapy","volume":"15","author":"Qiu","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: Results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s12185-017-2294-1","article-title":"NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib","volume":"106","author":"Hara","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"E916","DOI":"10.1002\/ijc.27537","article-title":"Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib","volume":"131","author":"Hassold","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/hon.2034","article-title":"Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study","volume":"31","author":"Uchiyama","year":"2013","journal-title":"Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1038\/s41375-020-0904-z","article-title":"Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey","volume":"34","author":"Breccia","year":"2020","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.3389\/fimmu.2020.586765","article-title":"Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?","volume":"11","author":"Ahmed","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1158\/2326-6066.CIR-17-0462","article-title":"Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML","volume":"6","author":"Ureshino","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","article-title":"KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib\/nilotinib strategy","volume":"126","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/cas.12216","article-title":"Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib","volume":"104","author":"Mizoguchi","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8950","DOI":"10.4081\/hr.2020.8950","article-title":"Treatment-free remission in chronic myeloid leukemia: Lights and shadows","volume":"12","author":"Molica","year":"2020","journal-title":"Hematol. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: The IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year Results of the Dasatinib Discontinuation Trial in Patients with Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment","volume":"18","author":"Okada","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","article-title":"Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients","volume":"43","author":"Caocci","year":"2015","journal-title":"Exp. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3892\/ol.2016.4192","article-title":"A case of myeloproliferative neoplasm with a normal complete blood cell count: A novel problem of the JAK2 era","volume":"11","author":"Ye","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: Ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms","volume":"75","author":"Rudolph","year":"2015","journal-title":"Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular Events and Intensity of Treatment in Polycythemia Vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"New Engl. J. Med."},{"key":"ref_101","first-page":"430","article-title":"Analysis of Natural Killer cell functions in patients with hereditary hemochromatosis","volume":"19","author":"Claus","year":"2020","journal-title":"EXCLI J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-018-0101-8","article-title":"Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-017-0041-8","article-title":"Essential thrombocythemia treatment algorithm","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ajh.23160","article-title":"Hydroxyurea-related toxicity in 3411 patients with Ph\u2019-negative MPN","volume":"87","author":"Antonioli","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"230","DOI":"10.5492\/wjccm.v4.i3.230","article-title":"Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients","volume":"4","author":"Michiels","year":"2015","journal-title":"World J. Crit. Care Med."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Singh, A., and Xu, Y.-J. (2016). The Cell Killing Mechanisms of Hydroxyurea. Genes, 7.","DOI":"10.3390\/genes7110099"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Freissmuth, M. (2020). Chemotherapie von Tumorerkrankungen, Springer Science and Business Media LLC.","DOI":"10.1007\/978-3-662-58304-3_61"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s11899-019-00538-4","article-title":"Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors","volume":"14","author":"Economides","year":"2019","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.leukres.2013.07.007","article-title":"Modest activity of pomalidomide in patients with myelofibrosis and significant anemia","volume":"37","author":"Daver","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.06.007","article-title":"Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis","volume":"48","author":"Chihara","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-017-0029-4","article-title":"Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: A retrospective analysis of incidence and durability of anemia response","volume":"8","author":"Luo","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/sj.bjc.6600607","article-title":"Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects","volume":"87","author":"Dredge","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-018-0078-3","article-title":"The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting","volume":"8","author":"Rocca","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_116","first-page":"319","article-title":"Mechanism Action of Platelets and Crucial Blood Coagulation Pathways in Hemostasis","volume":"11","author":"Periayah","year":"2017","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: Minimal residual disease and cure?","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin. Immunopathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.leu.2403217","article-title":"Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study","volume":"18","author":"Michallet","year":"2003","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-Stimulated Genes: A Complex Web of Host Defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2015","journal-title":"Leukemia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12687","article-title":"Interferon-\u03b1 induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera","volume":"97","author":"Riley","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_122","first-page":"241","article-title":"Hydroxyurea and Zileuton Differentially Modulate Cell Proliferation and Interleukin-2 Secretion by Murine Spleen Cells: Possible Implication on the Immune Function and Risk of Pain Crisis in Patients with Sickle Cell Disease","volume":"15","author":"Kuvibidila","year":"2015","journal-title":"Ochsner. J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/CDLI.8.4.702-705.2001","article-title":"In Vitro Hydroxyurea Decreases Th1 Cell-Mediated Immunity","volume":"8","author":"Weinberg","year":"2001","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1349-7006.2009.01439.x","article-title":"Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis","volume":"101","author":"Lu","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40164-016-0057-y","article-title":"Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2 V617F allelic burden","volume":"5","author":"Kelley","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.2147\/OTT.S102504","article-title":"Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: Comparative lessons learned","volume":"9","author":"Linder","year":"2016","journal-title":"Onco. Targets Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: Results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/2326-6066.CIR-16-0233","article-title":"Human dendritic cells mitigate NK-cell dysfunction mediated by nonselective JAK1\/2 blockade","volume":"5","author":"Curran","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_132","first-page":"1","article-title":"Transient blocking of NK cell function with small molecule inhibitors for helper dependant adenoviral vector-mediated gene delivery","volume":"5","author":"Munegowda","year":"2015","journal-title":"Cell Biosci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/156800911793743682","article-title":"Immunotherapy for myeloproliferative neoplasms (MPN)","volume":"11","author":"Hofmann","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/abbs\/gmt142","article-title":"Mechanism of immunomodulatory drugs\u2019 action in the treatment of multiple myeloma","volume":"46","author":"Chang","year":"2013","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3892\/ijmm.2016.2724","article-title":"Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review)","volume":"38","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"80105","DOI":"10.18632\/oncotarget.21049","article-title":"Molecular response prediction in CML: Novel ideas?","volume":"8","author":"Wolf","year":"2017","journal-title":"Oncotarget"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1535-7163.MCT-06-0358","article-title":"Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells","volume":"6","author":"Markasz","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e27601","DOI":"10.1002\/pbc.27601","article-title":"Characterization of natural killer cells expressing markers associated with maturity and cytotoxicity in children and young adults with sickle cell disease","volume":"66","author":"Abraham","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s11899-015-0284-z","article-title":"Immunological Consequences of JAK Inhibition: Friend or Foe?","volume":"10","author":"McLornan","year":"2015","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jaci.2017.08.040","article-title":"Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations","volume":"141","author":"Mace","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_142","first-page":"1","article-title":"Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy","volume":"5","author":"Cao","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40259-017-0225-6","article-title":"Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches","volume":"31","author":"Cayssials","year":"2017","journal-title":"BioDrugs"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Swatler, J., Turos-Korgul, L., Kozlowska, E., and Piwocka, K. (2021). Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias. Cancers, 13.","DOI":"10.3390\/cancers13061203"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4400\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:53:31Z","timestamp":1760165611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/17\/4400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":144,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["cancers13174400"],"URL":"https:\/\/doi.org\/10.3390\/cancers13174400","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]}}}